Screener
Vir Biotechnology, Inc. VIR Business Segments — Cost of revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:20 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053549
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Segment revenue | $238,946 | $1,214 | $238,917 | $4,246 |
| Less: Segment expenses (1) | ||||
| Cost of revenue | — | 11 | — | 11 |
| Research and development | ||||
| Contract manufacturing | 23,967 | 14,063 | 59,974 | 23,399 |
| Personnel (2) | 28,512 | 33,165 | 60,040 | 66,883 |
| Clinical costs | 22,532 | 20,361 | 48,666 | 40,967 |
| Licenses, collaborations and contingent consideration, net | 41,211 | 11,301 | 38,402 | 47,892 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Vir Biotechnology, Inc.'s business segments — cost of revenue?
- Vir Biotechnology, Inc. (VIR) reported business segments — cost of revenue of $0 in Q2 2026.
- How has Vir Biotechnology, Inc.'s business segments — cost of revenue changed year-over-year?
- Vir Biotechnology, Inc.'s business segments — cost of revenue decreased by 100.0% year-over-year, from $11K to $0.
- What is the long-term trend for Vir Biotechnology, Inc.'s business segments — cost of revenue?
- Over 2 years (2022 to 2025), Vir Biotechnology, Inc.'s business segments — cost of revenue has grown at a -98.7% compound annual growth rate (CAGR), from $146.32M to $26K.
- What does business segments — cost of revenue mean?
- This metric represents the direct costs attributable to the production and delivery of products or services within the company's primary reportable business segment. It encompasses expenses such as raw materials, direct labor, and manufacturing overhead required to generate the segment's reported revenue. Monitoring this figure helps investors assess the gross margin efficiency and production scalability of the company's core operational activities.
Ask your AI about Vir Biotechnology, Inc.'s business segments — cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude